The Norwegian Bank (DNB) has initiate the monitoring of Isofol Medical AB. Â For more information, please contact: Anders Rabbe, CEO, Isofol Medical AB EÂ-mail: anders.rabbe@isofolmedical.com Phone: +46 (0) 31 797 22 80 About arfolitixorin Arfolitixorin is a new drug developed to increase the efficacy of the cytotoxic agent 5-fluorouracil (5-FU) and as a …
In connection to this year’s major cancer congress ASCO (American Society of Clinical Oncology) in Chicago in June, Redeye brings together the seven most interesting cancer companies in the Nordic region for a discussion about the major changes in progress and how the companies position themselves in this fast growing theraputic area worth over $ …
Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th Read More »
Isofol Medical AB (publ) announces that a scientific abstract has been published for this year’s annual Congress of the American Society of Clinical Oncology (ASCO). The abstract presents results from a retrospective study in patients treated with 5-FU and the folate leukovorin (LV) for metastatic colorectal cancer (mCRC). The study shows a clear correlation between …
In March 2018, Isofol Medical AB (publ) submitted a Special Protocol Assessment (SPA) to the United States Food and Drug Administration (FDA). The SPA process aims to confirm the specific targets to be met in the ISO-CC-007 study, the pivotal study with arfolitixorin in first line metastatic colorectal cancer (mCRC). In the feedback received from …
Isofol reports FDAs feedback from the ongoing special protocol assessment (SPA) process Read More »
Isofol Medical AB (publ) announces that an abstract describing correlation between expression levels of folate-related genes in tumours with progression-free survival (PFS) in metastasizing colorectal cancer (mCRC) patients, treated with 5-FU/folate based therapy has been accepted for presentation at ASCO 2018, taking place 1-5th of June in Chicago, USA. The accepted abstract describes a gene …
On April 10th, Redeye will organize an investor specialist event focusing on late-stage drugs aimed to treat colorectal cancer. Isofol Medical, along with Pledpharma, will present future development plans, upcoming milestones, pivotal study design and what obstacles remains in order be granted market authorisation. Moderating analysts will be Klas Palin and Arvid Necander. Link for …
The selected dose for the drug candidate arfolitixorin of 120 mg/m2, (approximately 200 mg for an adult male) is based on safety and efficacy data from more than 115 individuals. The dose selection is an important milestone for the planned phase III pivotal trial, which is the last step in the drug development process prior …
Isofol Medical AB (publ) today announce that the company will in the future be adopting the generic name arfolitixorin for its lead candidate, up to now referred to as Modufolin®. Arfolitixorin was recently accepted by  World Health Organization (WHO) as the International Non-proprietary Name (INN) for the active ingredient of Isofol’s lead product Modufolin®. “We …
Isofol Medical AB (publ) has received positive feedback in scientific advice from the European Medicines Agency (EMA) regarding its candidate drug arfolitixorin (Modufolin®) intended for the treatment of advanced colorectal (colon) cancer. Thereby the significant parameters for the pivotal phase III study has been agreed upon with both the EMA and the FDA for the …
Isofol reports successful outcome from the scientific advice with the EMA Read More »
The incentive program consisting of stock – and employee options in Isofol Medical AB, which was initiated in 2012 with a duration until January 2018, has ended. The CEO, directors and employees have subscribed a total of 450 302 shares at SEK 17 per share corresponding to a total of SEK 7 655 136. After 450 302 newly issued …
